"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
Descriptor ID |
D000911
|
MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 12 | 10 | 22 |
1995 | 7 | 17 | 24 |
1996 | 4 | 11 | 15 |
1997 | 4 | 7 | 11 |
1998 | 6 | 16 | 22 |
1999 | 10 | 18 | 28 |
2000 | 7 | 12 | 19 |
2001 | 14 | 20 | 34 |
2002 | 11 | 16 | 27 |
2003 | 15 | 15 | 30 |
2004 | 23 | 16 | 39 |
2005 | 25 | 20 | 45 |
2006 | 26 | 15 | 41 |
2007 | 30 | 13 | 43 |
2008 | 23 | 21 | 44 |
2009 | 32 | 19 | 51 |
2010 | 40 | 24 | 64 |
2011 | 19 | 13 | 32 |
2012 | 17 | 11 | 28 |
2013 | 18 | 9 | 27 |
2014 | 18 | 13 | 31 |
2015 | 12 | 7 | 19 |
2016 | 16 | 6 | 22 |
2017 | 27 | 11 | 38 |
2018 | 23 | 14 | 37 |
2019 | 20 | 10 | 30 |
2020 | 14 | 12 | 26 |
2021 | 10 | 18 | 28 |
2022 | 4 | 19 | 23 |
2023 | 2 | 9 | 11 |
2024 | 8 | 2 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 Jul 08; 14(1):107.
-
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115.
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 May 29; 14(1):87.
-
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 Apr 22; 14(1):69.
-
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 Jul; 99(7):1257-1268.
-
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. Br J Haematol. 2024 Jun; 204(6):2227-2232.
-
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy. Eur Urol. 2024 Jun; 85(6):574-585.
-
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.
-
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. J Clin Oncol. 2024 Apr 20; 42(12):1403-1414.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.